News – Page 666 – Endpoints News

From cellist to synthetic cell-ist: Jeffrey Kim scores $23M to reimagine blood tests, cell therapy

4 years ago

Prepping for yet more pricey rare disease drugs, UK launches £340M 'Innovative Medicines Fund'

4 years ago

Hemab, still playing coy, gets its first major fundraise for hemophilia bispecifics

4 years ago

Inside Biogen's scramble to sell Aduhelm: Project 'Javelin' and pressure to ID as many patients as possible

4 years ago

Pfizer and BioNTech team up with South African manufacturer, but it will only handle fill-finish

4 years ago

In 60 days, most insurers will be required to cover HIV prevention drugs and related services with no cost-sharing

4 years ago

Building off Pfizer investment, microbiome-focused Vedanta expands new fundraise to launch 2 studies

4 years ago

AstraZeneca, Alexion close massive $39B merger; bluebird bio earns EU nod for Lenti-D as big split approaches

4 years ago

Novartis discards one of its ‘wild card’ drugs after it flops in key study. But it takes one more for the hand

4 years ago

FDA levels clinical hold on Magenta's second lead drug, asking for an additional bioassay before it gets to humans

4 years ago

As healthcare heats up on HKEX, Qiming sets up $500M fund dedicated to public companies

4 years ago

Healthcare venture capital has already blown away 2020 records, but does it have the juice to keep growing?

4 years ago

How cozy is too cozy? FDA and Biogen offer up a test case

4 years ago

Sanofi's sleeping sickness drug wins FDA OK and a lucrative priority review voucher too

4 years ago

Covid-19 roundup: Study shows J&J's shot is much less effective against Delta variant; Novartis open to manufacturing ...

4 years ago

After chiming in antibody to Covid-19 fight, Junshi drops $30M to kick off mRNA joint venture in China

4 years ago

IsoPlexis aims to steer its 'barcodes' to Nasdaq as Asia-focused SPAC launches merger efforts

4 years ago

The pivot: Turnstone Biologics opens a new chapter with a switch to clinical development and a new venture round to ...

4 years ago

New study shows smaller biopharma companies struggle more than larger ones with clinical trial transparency

4 years ago

On a mission to treat patients not covered by Luxturna, Horama refuels with a Series B expansion and a new name

4 years ago

Albireo caps a big week with back-to-back approvals in the US/EU for the first drug to treat a severe liver disease

4 years ago

A Novartis castoff with a troubled past headlines Chinese biotech's Hong Kong IPO quest

4 years ago

Relmada to explore psychedelic avenue in pursuit of depression treatment; Italian manufacturer joins NYSE

4 years ago

Delta variant's rapid rise — now spurring 83% of new cases — sends stocks spiraling in what CDC director calls a ...

4 years ago

First page Previous page 663 664 665666667 668 669 Next page Last page